Daiichi Sankyo discontinues development of Nafamostat in Japan for COVID-19 treatment

June 16, 2021 | Wednesday | News

In view of situations of ongoing non-clinical studies and the phase 1 trial

Image credit- shutterstock.com

Image credit- shutterstock.com

Japanese pharma firm Daiichi Sankyo Company has announced that it has decided to discontinue development of nafamostat inhalation formulation (DS-2319) for treatment of the novel coronavirus infectious disease (COVID-19).

DS-2319 is a drug product in inhalation dosage form that contains nafamostat mesilate.

Daiichi Sankyo proceeded with its development, expecting that nafamostat might exert a therapeutic effect by blocking membrane fusion between the envelope of the virus that causes COVID-19 and the host plasma cell membrane, and initiated a phase 1 trial in March 2021.

In view of situations of ongoing non-clinical studies and the phase 1 trial, however, Daiichi Sankyo has decided to discontinue the development of DS-2319.

 

Sign up for the editor pick and get articles like this delivered right to your inbox.

+Country Code-Phone Number(xxx-xxxxxxx)

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account